Gabapentin Toxicity in Patients with Chronic Kidney Disease: A Preventable Cause of Morbidity

American Journal of Medicine

Volumn 123, Issue 4, 2010, Pages 367-373

  Zand, Ladan ^a   McKian, Kevin P ^a   Qian, Qi ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Chronic kidney disease; Gabapentin; Mental status changes; Toxicity

Indexed keywords

GABAPENTIN;

ADULT; ARTICLE; ATAXIA; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONFUSION; CONSCIOUSNESS DISORDER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE PREDISPOSITION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; FLAPPING TREMOR; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MUSCLE WEAKNESS; MYOCLONUS; PRIORITY JOURNAL; SOMNOLENCE; TREMOR; UNSTEADINESS;

ADULT; AGE DISTRIBUTION; AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 77950148198     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.09.030     Document Type: Article

References (32)

1. Mathew N.T., Rapoport A., Saper J., et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41 (2001) 119-128
2. Nikolajsen L., Finnerup N.B., Kramp S., et al. A randomized study of the effects of gabapentin on postamputation pain. Anesthesiology 105 (2006) 1008-1015
3. Caraceni A., Zecca E., Bonezzi C., et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 22 (2004) 2909-2917
4. Caraceni A., Zecca E., Martini C., et al. Gabapentin for breakthrough pain due to bone metastases. Palliat Med 22 (2008) 392-393
5. Tai Q., Kirshblum S., Chen B., et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 25 (2002) 100-105
6. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
7. Morello C.M., Leckband S.G., Stoner C.P., et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159 (1999) 1931-1937
8. Huge penalty in drug fraud. Pfizer settles felony case in Neurontin off-label promotion. San Francisco Chronicle (2004) C-1
9. Anticonvulsants: Pfizer's pregabalin to top success of Neuronytin? BioNews (2003). www.bioportfolio.com/news/datamonitor_38.htm ed: BioPortfolio BioNews
10. Mula M. Anticonvulsants-antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab 9 (2008) 730-737
11. Bassilios N., Launay-Vacher V., Khoury N., et al. Gabapentin neurotoxicity in a chronic haemodialysis patient. Nephrol Dial Transplant 16 (2001) 2112-2113
12. Dogukan A., Aygen B., Berilgen M.S., et al. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 10 (2006) 168-169
13. Miller A., and Price G. Gabapentin toxicity in renal failure: the importance of dose adjustment. Pain Med 10 (2009) 190-192 Epub 2008 Aug 18
14. Hung T.Y., Seow V.K., Chong C.F., et al. Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. Emerg Med J 25 (2008) 178-179
15. Pierce D.A., Holt S.R., and Reeves-Daniel A. A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure. Clin Ther 30 (2008) 1681-1684
16. Lipson J., Lavoie S., and Zimmerman D. Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. Am J Kidney Dis 45 (2005) e100-e104
17. Tuccori M., Lombardo G., Lapi F., et al. Gabapentin-induced severe myopathy. Ann Pharmacother 41 (2007) 1301-1305
18. Poggio E.D., Wang X., Greene T., et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16 (2005) 459-466
19. Sagirli O., Cetin S.M., and Onal A. Determination of gabapentin in human plasma and urine by high-performance liquid chromatography with UV-vis detection. J Pharm Biomed Anal 42 (2006) 618-624
20. Zhu Z., and Neirinck L. High-performance liquid chromatographic method for the determination of gabapentin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 779 (2002) 307-312
21. MICROMEDEX. Table of Gabapentin Dosage in Renal Failure. In: GPT Dosage in Renal Failure M, gabapentin 1.3.2 and 1.3.5, 2008, ed., 2008.
22. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
23. Wen C.P., Cheng T.Y., Tsai M.K., et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371 (2008) 2173-2182
24. Blum R.A., Comstock T.J., Sica D.A., et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56 (1994) 154-159
25. Catterall W.A. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16 (2000) 521-555
26. Ji H.Y., Jeong D.W., Kim Y.H., et al. Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 20 (2006) 2127-2132
27. Johannessen S.I., Battino D., Berry D.J., et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25 (2003) 347-363
28. Brawek B., Loffler M., Dooley D.J., et al. Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch Pharmacol 376 (2008) 301-307
29. Field M.J., Cox P.J., Stott E., et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 103 (2006) 17537-17542
30. Wong M.O., Eldon M.A., Keane W.F., et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 35 (1995) 622-626
31. Krahenbuhl-Melcher A., Schlienger R., Lampert M., et al. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 30 (2007) 379-407
32. Bookwalter T., and Gitlin M. Gabapentin-induced neurologic toxicities. Pharmacotherapy 25 (2005) 1817-1819